Risvodetinib

DB21602InvestigationalSmall molecule

Risvodetinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Risvodetinib is a tyrosine kinase inhibitor. Risvodetinib is under investigation in clinical... Risvodetinib is under investigation in clinical trial NCT05424276 (A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease).

Mechanism: Pharmacologically active on Tyrosine-protein kinase ABL1 and Tyrosine-protein kinase ABL2
Curator reviewed
Formula / weight: C₃₃H₃₄N₈O₂ · 574.689 g/mol (avg)
Code names: IKT-148009

Resolves to

Compound

UNII2QG2B2XW2ICAS2031185-00-7ChEMBLCHEMBL5314481ChEBI759187PubChem122650693

Structure

InChIKeyADGOPPKEIZXKAZ-UHFFFAOYSA-NSMILESCN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC(=C3)C3=C(C)C=NO3)=C2)CC1

Targets

P00519ABL1P42684ABL2

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Risvodetinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account